A Phase 2 clinical trial evaluating Endeavor BioMedicines’ experimental oral therapy taladegib (ENV-101) in people with idiopathic pulmonary fibrosis (IPF), has dosed its first patient. The trial (NCT04968574) is enrolling adults, ages 40 and older, with mild-to-moderate IPF at one Australian site, with at least three more…
For Pulmonary Fibrosis Awareness Month, held each September, the biopharmaceutical company Boehringer Ingelheim Canada has created the Life with PF campaign to help patients better understand the stages of this progressive disease and to empower them to obtain much-needed care. The initiative, which is aimed at…
Cudetaxestat (BLD-0409), an investigational treatment for idiopathic pulmonary fibrosis (IPF) being developed by Blade Therapeutics, does not interact with the approved IPF treatment Ofev (nintedanib), according to research done in rats. “We believe that these are important data that help inform our step-wise approach to advance the clinical…
Adding co-trimoxazole or doxycycline — two broad-spectrum antibiotics — to standard care does not significantly slow lung function decline or prolong survival in people with idiopathic pulmonary fibrosis (IPF), a review study has found. This approach was instead associated with a higher risk of side effects, specifically gastrointestinal issues.
With reasonable safety, Ofev (nintedanib) slowed lung function decline in Japanese patients with progressive fibrosing interstitial lung diseases (ILDs), according to a subgroup analysis of the Phase 3 INBUILD trial. Overall, this analysis provides further assurance to clinicians in Japan on Ofev’s benefits to patients there, with “no new…
A large and multi-ethnic database, reported to be the first of its kind for rare lung diseases, is now compiling real-world clinical and imaging data on people with pulmonary fibrosis (PF) and other interstitial lung diseases (ILDs) from centers across the globe. Launched by the Open Source Imaging Consortium (OSIC),…
A newly launched non-profit institute is seeking to advance research, and the development of new therapies, for people with rare diseases — a patient community with some of the largest therapeutic needs, but one that is often left behind. Named the Institute for Life Changing Medicines, the project was…
A single dose of the investigational oral therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF) achieved therapeutic target engagement of up to 98% in the lungs of patients, according to interim results of a Phase 2a trial. At all doses tested, the anti-fibrotic, or anti-scarring, therapy engaged its intended target…
Blocking the activity of a cell death-suppressing protein called Bcl-2 promoted the death of macrophages — a type of immune cell involved in pulmonary fibrosis (PF) — and reversed established lung scarring in a mouse model, a study showed. Notably, Bcl-2’s anchoring at the surface of macrophage mitochondria was…
Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running an endurance race they are highly motivated to complete, but these incremental burdens negatively impact their ability or willingness to…
Get regular updates to your inbox.
